Mammoth makes Dx CRISPR

Mammoth Biosciences emerged from stealth with an exclusive license to Jennifer Doudna’s CRISPR-based diagnostics technology, which could enable faster diagnosis of a range of diseases than PCR-based sequencing and culture-based techniques and be more adaptable than antibody-based diagnostics.

Several studies in the past year, including work from Doudna, have described how the biology of Cas12 and Cas13 family members positions the enzymes to extend CRISPR applications to diagnostics. Doudna, a UC Berkeley professor, is co-founder of Mammoth and two CRISPR therapeutics companies. ...